Tom 11, Nr 2 (2020)
WYBRANE PROBLEMY KLINICZNE
Opublikowany online: 2020-08-17
Wyświetlenia strony
316
Wyświetlenia/pobrania artykułu
57
Nowe wytyczne Europejskiego Towarzystwa Kardiologicznego (ESC) oraz Europejskiego Towarzystwa Miażdżycowgo (EAS) postępowania w dyslipidemiach
Forum Zaburzeń Metabolicznych 2020;11(2):55-61.
Streszczenie
Brak
Referencje
- 2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk European Heart Journal (2020) 41, 111188. \.
- Chapman RH, Kowal SL, Cherry SB, et al. The modeled lifetime cost-effectiveness of published adherence-improving interventions for antihypertensive and lipid-lowering medications. Value Health. 2010; 13(6): 685–694.
- Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003; 34(2): 154–156.
- Evidence fromgenetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017;38:24592472Value Health 2010;13:685694.
- Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38(32): 2459–2472.
- Koskinas KC, Siontis GCM, Piccolo R, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J. 2018; 39(14): 1172–1180.
- Kritharides L, Nicholls SJ, Fulcher J, et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015; 385(9976): 1397–1405.
- Mihaylova B, Emberson J, Blackwell L, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012; 380(9841): 581–590.
- Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015; 372(25): 2387–2397.
- Lindgren P, Graff J, Olsson AG, et al. IDEAL Trial Investigators. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin. Eur Heart J. 2007; 28(12): 1448–1453.
- Franssen R, Vergeer M, Stroes ESG, et al. Combination statin-fibrate therapy: safety aspects. Diabetes Obes Metab. 2009; 11(2): 89–94.
- Davies GM, Vyas A, Baxter CA. Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States. J Med Econ. 2017; 20(7): 723–731.
- Li Na, Li Q, Tian XQ, et al. Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs. 2014; 14(5): 367–376.
- Cuchel M, Meagher E, Theron Hd, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. The Lancet. 2013; 381(9860): 40–46.
- Lagace TA. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol. 2014; 25(5): 387–393.
- Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003; 34(2): 154–156.
- Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol. 2014; 54: 273–293.
- Nozue T. Lipid Lowering Therapy and Circulating PCSK9 Concentration. J Atheroscler Thromb. 2017; 24(9): 895–907.
